ATLANTA, GA – – (Globe Newswire – March 26, 2026) – –Holzer & Holzer, LLC is investigating whether ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) complied with federal securities laws. On March 24, 2026, Culper Research published a report alleging that “ADMA’s reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor. We estimate that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported.” Following this report, the price of the Company’s stock dropped.

If you purchased ADMA stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/adma-biologics/ to discuss your legal rights.